ibuprofen mepha 400mg õhukese polümeerikattega tablett
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - ibuprofeen - õhukese polümeerikattega tablett - 400mg 10tk; 400mg 100tk; 400mg 60tk; 400mg 20tk
azimepha 500 mg õhukese polümeerikattega tablett
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - asitromütsiin - õhukese polümeerikattega tablett - 500mg 2tk; 500mg 30tk; 500mg 6tk; 500mg 150tk
azimepha 250 mg õhukese polümeerikattega tablett
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - asitromütsiin - õhukese polümeerikattega tablett - 250mg 4tk; 250mg 6tk; 250mg 3tk; 250mg 100tk
elonva
n.v. organon - korifollitropiin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - suguhormoonid ja genitaalsüsteemi, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).
olfen geel
mepha investigacao desenvolvimento e fabricacao farmaceutica lda. - diklofenak - geel - 1% 50g 1tk
lofral tablett
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - amlodipiin - tablett - 10mg 30tk; 10mg 60tk
lofral tablett
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - amlodipiin - tablett - 5mg 20tk; 5mg 30tk; 5mg 10tk
xylo-mepha ninasprei, lahus
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - ksülometasoliin - ninasprei, lahus - 0,5mg 1ml 10ml 1tk
xylo-mepha ninasprei, lahus
mepha-investigacao, desenvolvimento e fabricacao farmaceutica, lda - ksülometasoliin - ninasprei, lahus - 1mg 1ml 10ml 1tk
staquis
pfizer europe ma eeig - crisaborole - dermatiit, atoopiline - muud dermatoloogilised preparaadid - staquis on näidustatud kerge kuni mõõduka atoopiline dermatiit täiskasvanud ja pediaatriliste patsientide alates 2 aasta vanusest, kellel ≤ 40% keha pinnast (bsa) mõjutatud.